Matthew A. Wikler

4.9k total citations · 2 hit papers
22 papers, 3.9k citations indexed

About

Matthew A. Wikler is a scholar working on Pharmacology, Epidemiology and Molecular Medicine. According to data from OpenAlex, Matthew A. Wikler has authored 22 papers receiving a total of 3.9k indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Pharmacology, 10 papers in Epidemiology and 6 papers in Molecular Medicine. Recurrent topics in Matthew A. Wikler's work include Antibiotics Pharmacokinetics and Efficacy (11 papers), Pneumonia and Respiratory Infections (10 papers) and Antibiotic Resistance in Bacteria (6 papers). Matthew A. Wikler is often cited by papers focused on Antibiotics Pharmacokinetics and Efficacy (11 papers), Pneumonia and Respiratory Infections (10 papers) and Antibiotic Resistance in Bacteria (6 papers). Matthew A. Wikler collaborates with scholars based in United States, Russia and India. Matthew A. Wikler's co-authors include Clinical, Richard Platt, Charles S Bryan, E. Patchen Dellinger, John F. Burke, Cyrus C. Hopkins, Susan Marino, A. W. Karchmer, Dori F. Zaleznik and Paul G. Ambrose and has published in prestigious journals such as New England Journal of Medicine, Clinical Infectious Diseases and The Journal of Infectious Diseases.

In The Last Decade

Matthew A. Wikler

22 papers receiving 3.8k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically : Approved standard

2006 2.5k citations Matthew A. Wikler, Clinical profile →
Performance Standards for Antimicrobial Disk Susceptibility Tests; Approved Standard

2012 496 citations Matthew A. Wikler, Clinical Medical Entomology and Zoology profile →

Peers

Matthew A. Wikler

PHARM

Martin Steinbakk Norway

Koné Kaniga United States

Naoki Kato Japan

Niels Frimodt‐Møller Denmark

Yin-Ching Chuang Taiwan

J. M. Andrews United Kingdom

Márió Gajdács Hungary

Víctor Lorian United States

Derek F. J. Brown United Kingdom

Jennifer M. Andrews United Kingdom

Martin Steinbakk Norway

Matthew A. Wikler

1.5k ×1.4

1.1k ×1.2

965 ×1.1

569 ×0.7

PHARM

408 ×0.7

Citations per year, relative to Matthew A. Wikler Matthew A. Wikler (= 1×) peers Martin Steinbakk

Countries citing papers authored by Matthew A. Wikler

Since Specialization

Citations

This map shows the geographic impact of Matthew A. Wikler's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Matthew A. Wikler with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Matthew A. Wikler more than expected).

Fields of papers citing papers by Matthew A. Wikler

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Matthew A. Wikler. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Matthew A. Wikler. The network helps show where Matthew A. Wikler may publish in the future.

Co-authorship network of co-authors of Matthew A. Wikler

This figure shows the co-authorship network connecting the top 25 collaborators of Matthew A. Wikler. A scholar is included among the top collaborators of Matthew A. Wikler based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Matthew A. Wikler. Matthew A. Wikler is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Corey, G. Ralph, Francis F. Arhin, Matthew A. Wikler, et al.. (2016). Pooled analysis of single-dose oritavancin in the treatment of acute bacterial skin and skin-structure infections caused by Gram-positive pathogens, including a large patient subset with methicillin-resistant Staphylococcus aureus. International Journal of Antimicrobial Agents. 48(5). 528–534. 28 indexed citations

Holland, Thomas L, et al.. (2016). Single-Dose Oritavancin Treatment of Acute Bacterial Skin and Skin Structure Infections: SOLO Trial Efficacy by Eron Severity and Management Setting. Infectious Diseases and Therapy. 5(3). 353–361. 12 indexed citations

Corey, G. Ralph, Samantha Good, Hai Jiang, et al.. (2014). Single-Dose Oritavancin Versus 7–10 Days of Vancomycin in the Treatment of Gram-Positive Acute Bacterial Skin and Skin Structure Infections: The SOLO II Noninferiority Study. Clinical Infectious Diseases. 60(2). 254–262. 169 indexed citations

Corey, Ralph, Matthew A. Wikler, Greg Moeck, Hai Jiang, & Samantha Good. (2014). 1331The SOLO Studies: A Single-Dose of Oritavancin (ORI) Compared to 7-10 Days of Vancomycin (VAN) in the Treatment of Acute Bacterial Skin and Skin Structure Infections (ABSSSI). Open Forum Infectious Diseases. 1(suppl_1). S55–S55. 2 indexed citations

Wikler, Matthew A. & Clinical. (2012). Performance Standards for Antimicrobial Disk Susceptibility Tests; Approved Standard. Medical Entomology and Zoology. 496 indexed citations breakdown →

Jones, Ronald N., et al.. (2008). Comparative in Vitro Activity of Zabofloxacin (DW-224a) Tested Against Multidrug-Resistant Neisseria gonorrhoeae. International Journal of Infectious Diseases. 12. e181–e181. 1 indexed citations

Jones, Ronald N., Douglas J. Biedenbach, Paul G. Ambrose, & Matthew A. Wikler. (2008). Zabofloxacin (DW-224a) activity against Neisseria gonorrhoeae including quinolone-resistant strains. Diagnostic Microbiology and Infectious Disease. 62(1). 110–112. 17 indexed citations

Wikler, Matthew A. & Clinical. (2006). Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically : Approved standard. 26. 2525 indexed citations breakdown →

Dean, Nathan C., et al.. (2006). Comparing Gatifloxacin and Clarithromycin in Pneumonia Symptom Resolution and Process of Care. Antimicrobial Agents and Chemotherapy. 50(4). 1164–1169. 5 indexed citations

10.

Chen, Yunhua, Elizabeth Garber, Qi Zhao, et al.. (2005). In Vitro Activity of Doripenem (S-4661) against Multidrug-Resistant Gram-Negative Bacilli Isolated from Patients with Cystic Fibrosis. Antimicrobial Agents and Chemotherapy. 49(6). 2510–2511. 42 indexed citations

11.

Bhavnani, Sujata M., Jeffrey Hammel, Brenda Cirincione, Matthew A. Wikler, & Paul G. Ambrose. (2005). Use of Pharmacokinetic-Pharmacodynamic Target Attainment Analyses To Support Phase 2 and 3 Dosing Strategies for Doripenem. Antimicrobial Agents and Chemotherapy. 49(9). 3944–3947. 96 indexed citations

12.

Ge, Yigong, Matthew A. Wikler, Daniel F. Sahm, Renée S. Blosser-Middleton, & James A. Karlowsky. (2004). In Vitro Antimicrobial Activity of Doripenem, a New Carbapenem. Antimicrobial Agents and Chemotherapy. 48(4). 1384–1396. 68 indexed citations

13.

Anzueto, Antonio, et al.. (2002). Efficacy and tolerability of gatifloxacin in community treatment of acute exacerbations of chronic bronchitis. Clinical Therapeutics. 24(6). 906–917. 10 indexed citations

14.

Gotfried, Mark H., et al.. (2002). Oral gatifloxacin in outpatient community-acquired pneumonia: results from TeqCES, a community-based, open-label, multicenter study. Diagnostic Microbiology and Infectious Disease. 44(1). 85–91. 13 indexed citations

15.

Sher, Lawrence, et al.. (2002). Community‐Based Treatment of Acute Uncomplicated Bacterial Rhinosinusitis with Gatifloxacin. Otolaryngology. 127(3). 182–189. 8 indexed citations

16.

Platt, Richard, Dori F. Zaleznik, Cyrus C. Hopkins, et al.. (1993). Perioperative antibiotic prophylaxis and wound infection following breast surgery. Journal of Antimicrobial Chemotherapy. 31(suppl B). 43–48. 59 indexed citations

17.

Platt, Richard, Dori F. Zaleznik, Cyrus C. Hopkins, et al.. (1992). Prophylaxis against Wound Infection following Herniorrhaphy or Breast Surgery. The Journal of Infectious Diseases. 166(3). 556–560. 57 indexed citations

18.

Platt, Richard, Dori F. Zaleznik, Cyrus C. Hopkins, et al.. (1990). Perioperative Antibiotic Prophylaxis for Herniorrhaphy and Breast Surgery. New England Journal of Medicine. 322(3). 153–160. 294 indexed citations

19.

Lentnek, Arnold, et al.. (1984). Efficacy of ceftizoxime administered twice daily in hospitalized patients with respiratory tract infections.. PubMed. 7(1). 33–9. 3 indexed citations

20.

Sohn, Chong Il, Donald Pitkin, Sarah F. Grappel, et al.. (1984). Five cephalosporins: pharmacokinetics and their relation to antibacterial potency.. PubMed. 6(4). 560–70. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact